Lakefront Biotherapeutics (LKFT) Income from Continuing Operations (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Income from Continuing Operations of 15960946.61 for Q1 2026, up 108.87% year-on-year from 7641677.35 in Q1 2025, and down 98.29% on a QoQ basis from 934332147.77 in Q4 2025.
Lakefront Biotherapeutics (LKFT) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Income from Continuing Operations for 13 consecutive years, with 15960946.61 the latest figure, recorded in Q1 2026.
- Quarterly Income from Continuing Operations rose 108.87% year-over-year to 15960946.61 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 559530977.2 (up 365.43% YoY) and the FY2025 annual result came in at 363567286.01, up 25021.37% from the prior year.
- Income from Continuing Operations slipped to 15960946.61 in Q1 2026 per LKFT's latest filing, from 934332147.77 in the prior quarter.
- Over the last five years, Income from Continuing Operations for LKFT reached as high as 934332147.77 in Q4 2025 and fell as low as 571807227.87 in Q3 2025.
- A 5-year average of 4810935.97 and a median of 13160441.15 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 2304.9% — and 2024, when it soared 8020.58%.
- Year by year, Income from Continuing Operations stood at 76351041.83 in 2022, then soared by 39.41% to 46257841.12 in 2023, then jumped by 147.06% to 21770203.16 in 2024, then surged by 4191.79% to 934332147.77 in 2025, then sank by 98.29% to 15960946.61 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 15960946.61, 934332147.77, and 571807227.87 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Lakefront Biotherapeutics | 1.85 Bn | -1.64 Bn | 1.91 Mn | 15.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.96 Mn |
| Dec 31, 2025 | 934.33 Mn |
| Sep 30, 2025 | -571.81 Mn |
| Jun 30, 2025 | 181.05 Mn |
| Mar 31, 2025 | -180.00 Mn |
| Dec 31, 2024 | 21.77 Mn |
| Sep 30, 2024 | -108.18 Mn |
| Jun 30, 2024 | 55.61 Mn |
| Mar 31, 2024 | 25.45 Mn |
| Dec 31, 2023 | -46.26 Mn |
| Sep 30, 2023 | -16.79 Mn |
| Jun 30, 2023 | -702,117.79 |
| Mar 31, 2023 | -13.16 Mn |
| Dec 31, 2022 | -76.35 Mn |
| Sep 30, 2022 | -41.91 Mn |
| Jun 30, 2022 | -86.00 Mn |
| Mar 31, 2022 | -11.22 Mn |
| Dec 31, 2021 | 3.46 Mn |
| Sep 30, 2021 | -200.28 Mn |
| Jun 30, 2021 | -73.20 Mn |